Power3 Medical Products, Inc. (OTCBB: PWRM - News) announced today that it has filed two provisional patent applications with the United States Patent and Trademark Office (USPTO) - one on Alzheimer's disease specific differential diagnosis in the clinical setting and the other on important differences in pathophysiology and therapeutic options for the genetically distinct groups of Alzheimer's disease patients.
“These provisional patent applications cover diagnosis, treatment options and therapy monitoring in neurodegenerative diseases. The combination of these disclosures forms a strong foundation for innovation in diagnosis and treatment for Alzheimer's disease, and other diseases, through the genome and proteome of the patient, i.e., Personalized Regenerative Medicine (PRM™).”
"These two provisional patent applications, along with the additional provisional patent application recently filed by the principals of Power3 and others (Business Wire, May 4, 2010) on the use of stem cell protein biomarkers to monitor stem cell therapy and three other recently filed provisional patent applications on Parkinson's and Alzheimer's disease diagnosis, disclose a vast amount of invaluable information crucial to the accurate diagnosis and treatment of neurodegenerative diseases," stated Ira L. Goldknopf, Ph.D., President and Chief Scientific Officer of Power3 Medical Products, Inc. "These provisional patent applications cover diagnosis, treatment options and therapy monitoring in neurodegenerative diseases. The combination of these disclosures forms a strong foundation for innovation in diagnosis and treatment for Alzheimer's disease, and other diseases, through the genome and proteome of the patient, i.e., Personalized Regenerative Medicine (PRM™)."
Barcoding small extracellular vesicles with new CRISPR-based system